<-bsp-bb-link state="{"bbHref":"bbg://securities/LLY%20US%20Equity/MODL","_id":"00000190-353a-d5f2-a594-f73eaa4e0000","_type":"0000016b-944a-dc2b-ab6b-d57ba1cc0000"}">Eli Lilly & Co.-bsp-bb-link> broadened its effort to crack down on fake and off-brand versions of hit obesity drug Zepbound, saying it has filed more lawsuits against companies selling compounded versions of the treatment.
The drugmaker filed a handful of new lawsuits on Thursday against medical spas, wellness centers and other businesses, claiming they had referred to their products using Lilly’s brand names of Mounjaro and Zepbound. Lilly doesn’t provide its drug ingredients to compounders, the company said in a letter to patients.
Both Lilly and its rival <-bsp-bb-link state="{"bbHref":"bbg://securities/NOVOB%20DC%20Equity/MODL","_id":"00000190-353a-d5f2-a594-f73eaa4f0000","_type":"0000016b-944a-dc2b-ab6b-d57ba1cc0000"}">Novo Nordisk A/S-bsp-bb-link> issued multiple lawsuits last year in an attempt to ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.